FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to medicine, namely, to virology, pharmacy, and is intended for treatment of herpetic infections For this purpose applied is complex antiviral medication for external application, which contains (in wt %) recombinant interferon α - 2b (40-50) 106 IU, hyaluronic acid - 0.5-1.0, chitosan succinate - 1.0-2.0, licorice root extract - 0.2-0.5, zinc oxide - 0.8-2.0, lidocaine or dicaine - 0.8-1.0, polyethylenoxide-1500 - 5.0-7.0, anhydrous lanolin - 22.0-27.0, medical vaseline - 35.0-40.0, glycerin - 5.0-8.0, distillated water to 100,0 Medication ensures prolonged anti-inflammatory, anesthetic, wound-healing impact on herpetic affection of mucous membranes and skin, including genital herpes, opthalmo-herpes and shingles.
EFFECT: application of medication makes it possible to reduce terms of herpetic rash regress and reduce cytopathic effect of virus on skin and epithelium cells.
2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AGENT FOR EXTERNAL USE WITH ANTIVIRAL ACTION | 2021 |
|
RU2819719C2 |
| IMPROVED MEDICINAL FORM OF INTERFERON INDUCTOR | 1998 |
|
RU2162687C2 |
| METHOD OF PREPARING ANTIHERPETIC VACCINE AND MEDICINAL FORM BASED ON SAID | 1997 |
|
RU2142816C1 |
| IMPROVED MEDICINAL FORM OF HUMAN INTERFERON: SUPPOSITORY | 1997 |
|
RU2148988C1 |
| AGENT FOR WOUNDS, BURNS AND INFECTIOUS INFLAMMATORY DISEASES OF SKIN, APPENDAGES AND MUCOUS MEMBRANES | 2010 |
|
RU2452475C2 |
| ANTIVIRUS AGENT WITH HUMAN LEUKOCYTIC HUMAN INTERFERON BASED ON CHITOSAN SUCCINATE | 2009 |
|
RU2404796C1 |
| OINTMENT WITH BEE MOTH LARVAE EXTRACT AND PROPOLIS EXTRACT FOR PREVENTION AND INTEGRATED TREATMENT OF VIRAL INFECTION | 2011 |
|
RU2477141C2 |
| PHARMACEUTICAL ANTI-HERPETIC COMPOSITION | 2004 |
|
RU2291690C2 |
| MEANS FOR NASAL APPLICATION | 2016 |
|
RU2629330C1 |
| ANTIVIRAL GEL AS GEL BASED ON HUMAN LEUKOCYTE INTERFERON | 2005 |
|
RU2302881C2 |
